28 October 2020BiotechnologySarah Morgan

LSPN Connect: Eldora Ellison on PTAB denials, CRISPR and section 101

Discretionary denials at the Patent Trial and Appeal Board, the CRISPR landscape and section 101 are top of mind for Eldora Ellison, director at Sterne Kessler Goldstein & Fox.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

LSPN Connect: Challenges in the US patent landscape

21 September 2020 Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.

Genetics

Webinar: Plenty to fight for in CRISPR IP battle

26 March 2020 Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.

Big Pharma

LSPN Connect: Monetising your IP portfolio

15 February 2021 Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.

More on this story

Big Pharma

LSPN Connect: Monetising your IP portfolio

15 February 2021 Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.

Genetics

Webinar: Plenty to fight for in CRISPR IP battle

26 March 2020 Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.

Americas

LSPN Connect: Challenges in the US patent landscape

More on this story

Big Pharma

LSPN Connect: Monetising your IP portfolio

15 February 2021 Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.

Genetics

Webinar: Plenty to fight for in CRISPR IP battle

26 March 2020 Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.

Americas

LSPN Connect: Challenges in the US patent landscape